# Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)

Type: Product

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/phesgo-pertuzumabtrastuzumabhyaluronidase-zzxf
Canonical HTML page: https://getfinancebrief.com/entity/phesgo-pertuzumabtrastuzumabhyaluronidase-zzxf

## Recent coverage (1 stories)

### HALO stock hits $103 as FY2026 EPS guidance of $8.65-$9.00 overshoots consensus by $0.63
2026-08-12 02:50:02 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme Therapeutics posted a massive Q2 beat and raised FY2026 EPS guidance to $8.65-$9.00, well above the $8.02 consensus, triggering a two-day stock surge past $103. With a forward P/E near 11.5x and a PEG ratio of 0.36, the market is repricing the stock after realizing the royalty growth was underestimated.
Full story: https://getfinancebrief.com/story/halozyme-fy2026-earnings-guidance-beat-stock-surge

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.